Phase II Study of Ponatinib for Advanced Cancers With Genomic Alterations in Fibroblastic Growth Factor Receptor (FGFR) and Other Genomic Targets (KIT, PDGFRá, RET FLT3, ABL1)
Phase of Trial: Phase II
Latest Information Update: 07 Aug 2017
At a glance
- Drugs Ponatinib (Primary)
- Indications Cancer
- Focus Therapeutic Use
- 02 Aug 2017 Planned primary completion date changed from 1 Aug 2017 to 31 Dec 2017.
- 10 Jun 2017 Biomarkers information updated
- 01 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.